Search

One Year Later #4: The Cruel Irony of Lenacapavir for PrEP

In the fourth installment of our ‘One Year Later’ series we focus on lenacapavir and how science is breaking through formidable barriers in understanding HIV and how to prevent it, just as the infrastructure for delivering groundbreaking technology is defunded and destabilized.

One Year Later #3: The Undermining of the US Research Enterprise

This third installment of our ‘One Year Later’ series examines this administration’s sustained assault on the research enterprise. What has unfolded is a 365-day cascade of policy, programmatic and, financial actions that threaten US leadership and the scientific ecosystem responsible for lifesaving breakthroughs.

One Year Later

One Year Later #2: An Assault on Vaccine Science and Policy, and the Stakes for Global Health

The second piece in AVAC’s ‘One Year Later’ series is out. From cuts to HIV vaccine research to attacks on ACIP and Gavi, we break down how ideology is undermining evidence and why global health depends on defending science.

One Year Later #1: The Foreign Aid Freeze & Abuse of Executive Power

AVAC’s ‘One Year Later’ series reflects on the tumultuous events of the past 365 days across five global health issues. First up: how the foreign aid freeze and abuse of executive power are costing lives.

Global Health Watch: Health Policy Decisions Reversed, FY26 US Global Health Funding, America First MoUs Scrutinized & LEN for PrEP Advances

The US foreign assistance budget, if enacted, would restore some global health funds in a broader context of uncertainty, as US bilateral “America First” health MoUs advance without transparent plans for implementation or accountability. At the same time, abrupt reversals by the US Department of Health and Human Services of troubling health policy decisions underscore the Administration’s instability. Meanwhile, momentum around lenacapavir continues, recently approved by Brazil and with additional funding from Unitaid to reach more populations in South Africa and Zambia.

Lenacapavir Implementation Studies

Ongoing and planned implementation studies for the lenacapavir as of January 2026.

The Injectors of Tomorrow are Here Today

HIV Prevention Product Overview

The graphic provides an overview of PrEP products currently available and in late-stage clinical trials. 

Lenacapavir Regulatory Approval

Regulatory approvals, pending decisions, and appeals as of January 2026.